GLP-1 & compounded medication availability in Rhode Island (2026)

Rhode Island keeps its pharmacy oversight inside the Department of Health, and keeps the rules simple: an out-of-state pharmacy needs a Rhode Island nonresident license before anything ships across the border, and a telemedicine prescription must rest on a real clinical evaluation, and the state is explicit that an online questionnaire alone is not one. Both suit us fine. Here is what actually reaches Rhode Island addresses, across all ten lines we track.

Baseline state

Availability facts last reviewed: November 16, 2026

What ships to Rhode Island, line by line

Availability of all ten OrderlyMeds product lines in Rhode Island, with typical delivery times and notes
Product lineAvailable in Rhode Island?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Filled by partner pharmacies licensed for Rhode Island.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Flat national pricing at every dose, Providence to Westerly.
NAD+ Yes 8–10 business days Same telehealth evaluation flow as every other line.
Sermorelin Yes 8–10 business days Dispensed by licensed partner pharmacies into the state.
Glutathione No N/A Not part of the OrderlyMeds formulary at present.
BPC-157 Yes 8–10 business days Patient-specific compounded injectable; federal record below.
TB-500 Yes 8–10 business days Patient-specific compounded injectable; see the section below.
KPV No N/A Not carried anywhere. Ours is an injectable-only formulary, and KPV is not injectable for us.
Epitalon Yes 8–10 business days Patient-specific compounded injectable; its federal section follows.
MOTS-c Yes 8–10 business days Patient-specific compounded injectable with its own distinct federal record, below.

Two of the ten rows below are honest gaps rather than quiet omissions, and that is deliberate. Rhode Island facts were last reviewed on November 16, 2026.

Research peptides in Rhode Island: BPC-157, TB-500, KPV, Epitalon & MOTS-c

Four of the five research-peptide lines reach Rhode Island through OrderlyMeds: BPC-157, TB-500, Epitalon and MOTS-c, each a compounded injectable dispensed on a patient-specific prescription. The fifth, KPV, is one we do not compound at all, because it is not an injectable line and ours is an injectable-only peptide formulary. Rhode Island adds no peptide-specific rules of its own, so what follows is the federal record for each line, stated in full whether the row above says Yes or No.

BPC-157 in Rhode Island

Reaches Rhode Island as a compounded injectable, dispensed on a patient-specific prescription by a licensed pharmacy. Two federal facts below complete the picture.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Rhode Island

A compounded injectable in our Rhode Island offering, patient-specific prescription required. Read its federal record before deciding.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Rhode Island

Not compounded by our partner pharmacies in any form, because the formulary is injectable-only and KPV falls outside it, in Rhode Island as everywhere.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Rhode Island

Orderable for Rhode Island addresses as a compounded injectable on a patient-specific prescription. Federal facts stated next.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Rhode Island

Ships to Rhode Island as a compounded injectable, patient-specific prescription required, and its federal record below is deliberately not a name-swap of the other four.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Rhode Island’s pharmacy regulators say about compounded medications

Rhode Island’s pharmacy rules live with the Department of Health, which licenses both the pharmacies inside the state and every out-of-state pharmacy that ships into it. The state’s telemedicine standard is equally plain-spoken: a prescription issued remotely must rest on the same quality of evaluation as one issued across a desk.

Under R.I. Gen. Laws §5-19.1-11, a pharmacy located outside Rhode Island that ships, mails, or delivers legend drugs into the state must hold a nonresident pharmacy license from the Department of Health, maintain its home-state license in good standing, and comply with Rhode Island’s pharmacy regulations when dispensing to residents. Source: R.I. Gen. Laws §5-19.1-11.

Rhode Island permits prescriptions issued via telemedicine where the encounter meets the same standard of appropriate practice as a face-to-face setting; treatment or prescribing based solely on an online questionnaire does not meet that standard. Source: CCHP Policy Finder — Rhode Island.

No GLP-1-specific or peptide-specific restriction has been published by Rhode Island’s pharmacy regulators; compounding into the state is governed through the licensure framework above. Source: Rhode Island Department of Health.

For a Rhode Island patient the sequence is the standard one: online eligibility check, a genuine evaluation by a provider licensed for Rhode Island, since the questionnaire-alone shortcut the state rules out is a shortcut we never used, then fulfillment by a licensed pharmacy, tracked to your door within the published window. The smallest state pays the same flat national price as the largest.

Rhode Island availability FAQs

Is compounded semaglutide available in Rhode Island?

Yes. OrderlyMeds ships compounded semaglutide to Rhode Island addresses from pharmacies licensed for the state, at the flat national price.

Can a Rhode Island prescription really start online?

Yes, provided the evaluation is real: the state’s standard requires remote prescribing to match in-person care, and rules out questionnaire-only prescribing. OrderlyMeds’ provider evaluation meets that bar, with the details cited in the regulator section above.

Do research peptides ship to Rhode Island?

Four do: BPC-157, TB-500, Epitalon and MOTS-c, as compounded injectables on patient-specific prescriptions. KPV doesn’t, because we compound injectables only. Each section above carries that line’s cited federal record.

How fast is delivery to Rhode Island?

The published window is 8–10 business days from signup; tracking arrives by email as soon as the order ships.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone